Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Pharmaceutical
Swiss pharma giant Novartis’ $3.9 billion acquisition of France’s Advance Accelerator Applications hit the headlines last week in the M&A space, as did Neos Therapeutics’ rejection of a renewed unsolicited bid from PDL Biopharma. On the regulatory front, AstraZeneca won US Food and Drug Administration approval for its leukemia treatment Calquence, an FDA advisory panel backed approval of two new opioid use disorder drug candidates – Indivior’s RBP-6000 and Braeburn’s CAM2038, and Breakthrough designation for GlaxoSmithKline and Seattle Genetics’ myeloma candidate GSK2857916. There was also positive clinical trial news from Alnylam on patisiran and Ionis on inotersen. 5 November 2017
Pharmaceutical
After the excitement of August's $11.9 billion takeover of Kite Pharma by US biotech Gilead Sciences, this fall has so far been a relatively quiet one for major pharma M&A deals are concerned. 3 November 2017
Generics
Indian generic drugmaker Alembic Pharmaceuticals has completed a buy of a New-Jersey based company that takes its number of abbreviated new drug application (ANDA) approvals in the USA to 69. 1 November 2017
Biotechnology
Shares of France-based Advanced Accelerator Applications (AAA; (Nasdaq: AAAP) moved up 5.68% and a further 2.88% to $75.1012 in after-hours trading on Friday, ahead of the confirmation that is has received a takeover approach, which its board of directors had agreed to. 30 October 2017
Pharmaceutical
Japan may have the dubious distinction of being the least understood pharma market in the developed world, writes long-time Japanese industry watcher P Reed Maurer, president of International Alliances Limited, in his exclusive column for The Pharma Letter. 30 October 2017
Biotechnology
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion. 27 October 2017
Pharmaceutical
PDL BioPharma has submitted an unsolicited proposal to acquire fellow US drugmaker Neos Therapeutics for $10.25 per share in cash. 27 October 2017
Biotechnology
San Franciscan firm Vir Biotechnology has announced a series of strategic deals aimed at boosting its research and development clout in the area of serious infectious diseases. 18 October 2017
Generics
Shares in Impax Laboratories were worth 10% less at $18 after Tuesday morning’s trading. 17 October 2017
Biotechnology
Belgian biotech firm Ablynx saw its shares gain 2.3% to 18.28 euros as markets opened this morning and following the announcement that it is establishing a subsidiary in the USA. 16 October 2017
Biotechnology
Israeli pharma firm Alcobra and privately-held USA-based Arcturus Therapeutics have signed a definitive agreement to merge the two companies in an all-stock transaction. 16 October 2017
Pharmaceutical
Confirming an option agreement earlier this year, Indian pharma major Lupin via its US subsidiary, said today that it has now acquired Symbiomix Therapeutics. 12 October 2017
Pharmaceutical
In another Big Pharma move to realign their operations, US giant Pfizer yesterday announced that it is reviewing strategic alternatives for its Consumer Healthcare business. 11 October 2017
Pharmaceutical
Kitov Pharmaceuticals has acquired an additional 27% stake in TyrNovo, a privately-held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders, also based in Israel. 6 October 2017
Pharmaceutical
An analysis from the investment research firm Zacks has considered the impact that US President Donald Trump’s proposed tax reforms could have on large-cap pharma companies based in the USA. 2 October 2017
Pharmaceutical
News last week attracted a great deal of comment included Neos Therapeutics gaining US Food and Drug Administration for its attention deficit hyperactivity disorder (ADHD) drug Adzenys. Also garnering attention were: Ultragenyx’ rival bid to acquire Dimension Therapeutics; supplemental approval for Ipsen’s Somatuline Depot; an FDA safety alert on Intercept Pharmaceuticals’ Ocaliva; and a Phase III success for Nabriva’s lefamulin 23 September 2017
Biotechnology
USA-based Catalent has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. 19 September 2017
Biotechnology
Shares in Dimension Therapeutics, a USA-based gene therapy company focused on rare diseases, had rocketed by nearly 38% to $5.76 by Monday lunchtime amid news of a potential takeover to rival the bid made by the biotech firm Regenxbio. 18 September 2017
Biotechnology
Inotek Pharmaceuticals and USA-based gene therapy start-up Rocket Pharmaceuticals have entered into a definitive merger agreement. 13 September 2017
Pharmaceutical
Specialty pharma firm Clinigen Group and fellow London-listed CSO Quantum Pharma have agreed the terms of a takeover deal. 13 September 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze